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Abstract
Background: In plastic surgery, skin flap is an important approach to reconstructive wound repairs. The rat dorsal
skin flap is a clinically relevant and popular animal model to investigate and evaluate flap survival and necrosis.
Nonetheless, flap survival is often unstable with unpredictable outcomes, regardless of previous attempts at design
modification.
Methods & Results: In the present study, we report a novel flap chamber that provides stable and reproducible
outcomes by separating the dorsal skin flap from its surrounding skin by in situ immobilization. The flap chamber
blocks circulation that disturbs flap ischemia from both basal and lateral sides of the flap tissue. Demarcation of skin
necrosis is macroscopically evident on the flap and supported by distinct changes in histological architecture under
microscopic examination. The utility of the novel skin flap chamber is further proven by applying it to the
examination of flap survival in streptozotocin-induced diabetic rats with an increase in skin necrosis. The flap
chamber also affords size modifications where a narrower flap chamber increases ischemia and provides
manipulable therapeutic windows for studying cell therapies. Accordingly, intradermal injection of endothelial cells
3 days before flap ischemia significantly increases the survival of skin flaps.
Conclusions: The novel flap chamber not only may stabilize the skin flap and provide reproducible outcomes that
overcome the shortfalls of the traditional ischemic flap but also may afford size modifications that support research
designs and test therapeutic approaches to regenerative repair.
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Introduction
Surgical skin flaps are often used to repair wounds
resulting from trauma, congenital defects, tumor exci-
sion, or other causes. Partial skin flap necrosis is a com-
mon problem in the clinic, especially at the distal part of
the flap [1]. Flap necrosis is caused primarily by inad-
equate blood perfusion or ischemia-reperfusion and in-
duces several detrimental changes in the tissue and
vasculature, such as reactive oxygen species and super-
oxide dismutase activities [2]. Common ischemic factors
such as poor surgical technique and handling, smoking,
and diabetes mellitus may jeopardize skin flap survival.
Management of the necrotizing flap, which is very time-
consuming, requires repetitive dressing changes and in
some cases a secondary reconstructive procedure. There-
fore, the augmentation of perfusion in surgical flaps has
long been a challenging clinical goal.
To explore novel mechanisms of blood vessel forma-
tion and interacting signals during tissue hypoxia, an
animal model is needed to create a reproducible ische-
mic gradient in surgical flaps [3]. The dorsal rat flap
model, first described by McFarlane et al. in 1965, is one
of the most frequently used models to study angiogen-
esis and ischemia-reperfusion [4]. Many approaches to
enhance the survival of surgical flaps have been tested in
the prevention of ischemic injuries, such as precondi-
tioning with transient remote ischemia [5], vascular
endothelial growth factor treatment [6], or platelet-rich
plasma treatment [7]. The concepts of tissue engineering
and regeneration were also proposed by applying various
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stem cell therapies to promote vasculogenesis in the ische-
mic flap [8–11]. However, the variability of flap necrosis
leads to difficulties in comparative results between differ-
ent therapeutic interventions [12]. The uncertain vascular
distribution in the flap is one of the causes of necrosis
variability. Modification of flap size according to rat size
and the underlying bony landmarks is suggested to reduce
this variation [13, 14]. Collateral vessel compensation from
the surrounding skin and wound bed is an additional rea-
son for the extensive variability [15].
Despite several modifications and standardization pro-
posals to help to stabilize ischemic flap survival, the ex-
tent of flap necrosis is still highly variable (25 % to 50 %
necrosis of flap length) [12, 14, 16]. A reliable flap model
is therefore highly demanded, especially for cell therap-
ies of the ischemic flap of either healthy or circulation-
compromised skin. So far, there is no proposed flap
modification that is designed to stabilize the dorsal skin
flap and to isolate the ischemic skin flap from circulatory
interference from the adjacent skin. To minimize the
unpredictability of dorsal skin flap necrosis, we intro-
duce an innovative flap chamber and verify its reprodu-
cibility in both healthy and disease models, including
therapeutic approaches.
Methods
Animal housing and surgery for skin flap
All animal procedures complied with clause 16 of the
Animal Protection Act, and all experiments were moni-
tored and approved by Institutional Animal Care and
Use Committee of National Cheng Kung University. All
male Sprague-Dawley (SD) rats (8 weeks old, 270–300 g)
were housed in groups of two in an environmentally
controlled room, at consistent temperature and humid-
ity, on a 12:12 h light/dark cycle, with food and water ad
libitum.
All surgeries were conducted by the same surgeon and
followed an identical protocol. The SD rats were randomly
divided into suture (n = 8) or chamber model (n = 8)
groups, depending on the experimental treatment. Surgi-
cal anesthesia was induced and maintained by intraperito-
neal injection of Zoletil® (Virbac, Carros, France) at a
dosage of 50 mg/kg. After anesthesia, the surgical area of
dorsal skin was shaved and sterilized with 70 % ethanol.
To compare the common skin flap model with the new
developed chamber, the McFarlane flap was created in the
suture group according to previous studies [4, 16]. Briefly,
the three-sided full-thickness skin flap (3.6 × 7.2 cm in
original and 3 × 10 cm in narrow ones) was created on
the dorsal skin of rats by raising the skin from the iliac
crest to the scapular tip by using sharp dissection with
scissors. The three-sided island skin flap included skin,
subcutaneous tissue, and panniculus carnosus muscle. A
silicon membrane adjusted to the flap size was placed
beneath the flap as a barrier to prevent neovascularization
from the wound bed perturbing the flap. The flap was su-
tured in situ to the surrounding wound edge by 4-0 poly-
propylene sutures. The body weight of rats slightly
increased with normal activities after flap chamber
implantation.
Development of new skin flap chamber
To ameliorate the unpredictable flap survival pattern
and ratio in the traditional McFarlane flap, we designed
an innovative flap chamber to immobilize the ischemic
flap to the adjacent dorsal skin. The chamber was as-
sembled by top, middle, and bottom layers by using a
stainless plate with screws and nuts (Fig. 1a, detailed
scale in Additional file 1: Figure S1).
The process used in the suture group was repeated in
the chamber group to create three-sided skin flaps. The
adjacent skin was fixed between the middle and bottom
plates by inserting a silicon membrane beneath the flap
(Fig. 1b). The elevated three-sided ischemic flap was
then secured between the top and middle plates to sep-
arate the ischemic flap from the adjacent skin. The detail
of the ischemic flap chamber assembly with skin flap
model setup is described as follows (Fig. 1c): after flap
elevation, a bottom plate with a silicon membrane ad-
justed to size was implanted, the adjacent skin flap was
punched by a 2-mm punch biopsy and screws inserted
to stabilize the base of the chamber, a middle plate was
placed on the adjacent skin edge, the skin flap was then
punched and secured above the middle plate, rubber
gasket rings were placed above the skin flap to avoid
pressure loading on the skin flap from the top plate of
chamber, and finally the top plate was positioned onto
the skin flap and fixed by steel nuts. After the surgical
procedures, all rats were positioned under a warming
lamp until conscious. Animals were sacrificed by over-
dose of carbon-dioxide inhalation and the skin tissue
harvested after post-operation day 7 (POD7).
Diabetic state induction
After 48 h of fasting, SD rats (270 to 300 g) were intra-
peritoneally injected with a single shot of streptozotocin
(STZ) (Sigma-Aldrich, St. Louis, MO, USA) at a dosage
of 70 mg/kg. The STZ was freshly prepared by dissolving
in 50 mM sodium citrate buffer (pH = 4.5) prior to injec-
tion. The diabetic state was confirmed by monitoring
the elevation of blood glucose to more than 250 mg/dl
with fasting for 8 h after the STZ induction for 21 days.
Cell therapy in the skin flap chamber
Human umbilical vein endothelial cell (HUVEC) admin-
istration was used as a salvage therapy in ischemic tissue
[11]. The protocol for the isolation of HUVECs has been
described previously [17]. In brief, human umbilical
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cords were washed with normal saline to remove blood
clots. The umbilicus vein was perfused with 0.75 % type
I collagenase (Invitrogen, Waltham, MA, USA) to isolate
HUVECs from vessel walls and cultured in M199
medium (Invitrogen) supplemented with 20 % fetal bo-
vine serum (HyClone, part of GE Healthcare, Little
Chalfont, UK). To study the enrichment of endothelial
cells in preventing flap necrosis, the HUVECs were
transplanted by intradermal injection 3 days prior to flap
surgery [9, 10]. A total number of 1 × 106 cells was sus-
pended in 1 ml of normal saline and evenly injected into
the intradermal layers of skin along the middle axis.
Necrosis and histological assessment
To observe the gross changes due to skin necrosis, pho-
tographs of skin flaps were taken by using a digital cam-
era (IXUS-105, Canon, Tokyo, Japan) at the same focal
distance under 3 % isoflurane anesthesia (Panion & BF
Biotech Inc., Taipei, Taiwan) on PODs 3, 5, and 7. After
the rats were sacrificed, the necrotic edge of the skin flap
was judged by the skin’s appearance, consistency, and
the absence of blood flow perfusion [18]. An area of the
flap was assigned as a necrotic part if it exhibited a dar-
ker surface, abnormal stiffness, and lack of blood flow
after being cut by scissors. After the necrotic edge was
judged, the viable area of the flap was selected and quan-
tified by using ImageJ software (version 1.47 t, Wayne
Rasband, National Institutes of Health, Bethesda, MD,
USA). The ratio of viable to non-viable skin flap was cal-
culated as the viable area as a percentage of the necrotic
area in the entire skin flap.
The harvested skin tissues were fixed with 4 % para-
formaldehyde (Sigma-Aldrich), then dehydrated in a gra-
dient series of ethanol solutions and finally xylene
cleared and embedded in paraffin. The samples were
sectioned longitudinally to a thickness of 10 μm and
stained with hematoxylin and eosin (H&E) to observe
tissue morphology. The immunohistochemical (IHC)
stainings were used to determine vascular structures and
protein expressions by using specific antibodies in ac-
cordance with the established protocols [19]. The pri-
mary antibodies with specific dilution ratio were used
for von Willebrand factor (vWF) (1:100, Santa Cruz Bio-
technology, Inc., Dallas, TX, USA), alpha-smooth muscle
actin (α-SMA) (1:500, Abcam, Cambridge, UK), and B-
cell lymphoma 2 (Bcl2, 1:100, Santa Cruz Biotechnology,
Inc.). The digital images were taken with the same
microscope (BX51, Olympus, Tokyo, Japan).
Statistics
The data are expressed as the mean ± standard deviation.
Parametric analysis was performed for comparisons be-
tween the experimental groups. The Student’s t test was
used for the survival ratio of flaps and for fasting blood
glucose. Multiple comparisons among groups were per-
formed by using one-way analysis of variance followed
by the Bonferroni post hoc test. P values of less than
0.05 were considered to indicate statistical significance.
All statistical analyses were performed by using graphing
and analysis software (Origin version 8.5, OriginLab
Corporation, Northampton, MA, USA).
Results
Variable and unstable survival using the traditional
McFarlane flap
The survival ratio from the McFarlane flap revealed
highly variable survival with an unstable pattern 7 days
after surgery (Fig. 2). The necrotic regions of the distal
flaps either were located in the center (Fig. 2a) or were
crooked (Fig. 2b). Moreover, the survival area ranged
from 80 % to 100 % (Fig. 2a-d). After flap elevation,
some rats showed a clear demarcated line between the
c
a b
Fig. 1 Flap chamber composition and step-by-step assembly. a Three components of chamber. b The relationship between dorsal skin flap and
the flap chamber. c The protocols for step-by-step flap chamber assembly: marking of dorsal skin flap, raising of the full-thickness skin flap,
implantation of the bottom plate, placement of the middle plate, fixation of skin flap above the middle plate with rubber ring protection, covered
by top plate with iron nut fixation
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Fig. 2 Common discrete patterns of flap survival in suture model (flap size of 3.6 × 7.2 cm). Round shape skin necrosis (a). Unilateral skin necrosis





Fig. 3 Reproducible skin survival by flap chamber. Gross picture of flap survival between suture and chamber model (a). The box plot of survival
ratio distribution of dorsal flap (n = 8 in each group) (b). The skin contraction decreased the flap length in the suture model but not in the flap
chamber (c). Hematoxylin-and-eosin staining from cranial to caudal, across the skin necrosis line (black dotted line) (d). Quantification of skin
thickness and number of hair follicles were compared from cranial to caudal survival and death region (e)
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survival and necrotic areas (Fig. 2a,b) whereas other rats
did not distinguish a clear necrotic area (Fig. 2d). Lack
of a clear demarcation increases the difficulty in calculat-
ing the survival ratio. In addition, the contraction of the
flap was present in most cases of the McFarlane flap and
exhibited variable distorted patterns with different de-
grees of flap necrosis.
Highly stabilized ischemic model by flap chamber
The flap chamber achieved more stable results com-
pared with the traditional suture model in the McFar-
lane flap (Fig. 3a). From the distal to the proximal flap,
the necrotic skin showed a linear gradient of ischemic
pattern. The quantification of the survival area in the
flap chamber demonstrated highly repeatable skin necro-
sis with a small variation when assembling the three-
sided full-thickness skin in the flap chamber (Fig. 3b).
The quantification of flap length revealed a high degree
of skin contraction that distorted and shortened the sur-
vival area in the flap from the suture model, and this
could be prevented by using the flap chamber device;
that is, there was no flap length change in the chamber
group (Fig. 3c). In the longitudinal section of skin
histology using H&E staining (Fig. 3d), the flap chamber
provided a clear demarcation line and distinct micro-
scopic architecture between the proximal survival (cra-
nial) skin and the distal death (caudal) region. The full
thicknesses of both survival and death skin were signifi-
cantly decreased in the suture model, as compared with
the cranial base area. There were no significant changes
of skin thickness in both the survival and death regions
in the chamber model (Fig. 3e). The morphology of hair
follicles became apoptotic and shrunk in the death re-
gion of the ischemic flap without a significant difference
in the number of hair follicles. The image data also dem-
onstrated normal architecture of full-thickness skin in
the survival region of the flap chamber when compared
with the suture model.
Distinct pattern of vasculature across the demarcation
line by flap chamber
To verify the pattern of vasculature across the demarca-
tion line, the IHC stain of vWF and α-SMA revealed a
distinct difference of lumen number and vascular struc-
tures across the demarcation line in the chamber model
(Fig. 4). A similar difference in vasculature could be
Fig. 4 Immunohistochemical (IHC) stain of vascular pattern across the demarcation line. The IHC stain of both von Willebrand factor (vWF) and
alpha-smooth muscle actin (α-SMA) revealed increased signals in the cranial region as compared with the caudal region (black arrowhead: positive
staining). No positive staining of B-cell lymphoma 2 (Bcl2) was observed across the demarcation line
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found in suture model, but with a longer distance across
the demarcation line. There was no difference in Bcl2
signal across the demarcation line.
Application of flap chamber in a disease model
The stable results from the flap chamber indicate the
possibility of further investigating the necrosis of skin
flap in a diseased animal. Diabetic status was successfully
induced by intraperitoneal injection of STZ into adult
rats and showed an elevation of blood sugar 3 weeks
after induction (Fig. 5a). When the flap chamber in dia-
betic rats was used, increases in the necrosis area were
observed 7 days after surgery (Fig. 5b). The survival ratio
of the skin flap was significantly decreased by approxi-
mately 50 % compared with healthy, non-diabetic rats
(Fig. 5c). As compared with the healthy group (Figs. 3d
and 5d), the longitudinal section of skin histology using
H&E staining also revealed distinct differences in skin
architecture, skin thickness, and morphology of hair fol-
licles between the survival and necrotic regions of the
flap from diabetic rats (Fig. 5d). Consistent flap survival
in the diabetic rat model could permit a further survey
of flap physiology or the application of potential clinical
therapeutic modalities.
Chamber modification for cell therapy
The initial design of the flap chamber was developed to
scale (3.6 × 7.2 cm for a 1:2 width-to-length ratio,
20 g in chamber weight) to achieve an average of
20 % necrosis and to compare its stability with the
McFarlane suture using the same flap size. After con-
firmation that stable survival using the flap chamber could
be achieved, further versatile design modifications were
made to increase the challenge of therapeutic window for
advanced purposes in cell therapies. By changing the
chamber size to a narrow scale (3 × 10 cm for over 1:3 in
width-to-length ratio, 17 g in chamber weight), an average
necrosis area of 80 % was created in the age-matched rats
as compared with the initial flap chamber design (Fig. 6a).
The skin flap demarcation line remained clear in the nar-
row flap chamber. HUVECs from human umbilical cord
blood consisted of late endothelial progenitor cells, which
contributed to angiogenesis and protected the tissue from
ischemia in our previous study [17]. HUVECs were equally
implanted into the dermis of the skin flap for 3 days before
flap surgery (Fig. 6a, black spots in Narrow +HUVEC rat).
With the treatment of cell therapy, the extent of flap sur-
vival could be significantly salvaged to 40 %, as compared
with 20 % skin survival in the narrow flap chamber group
(Fig. 6b). The versatile property and tight control of the
percentage of skin survival using these flap chambers en-
abled researchers to study the different degrees of injury.
These results provide solid evidence that the newly devel-
oped flap chamber is an ideal platform to provide a con-
sistent in vivo microenvironment for skin necrosis, which




Fig. 5 Flap survival in streptozotocin (STZ)-induced diabetic rats. Significant increase of blood sugar indicates a successful diabetic model in
fasting rats 3 weeks after STZ induction (a). Gross picture of flap survival between healthy and diabetic rats (n = 4 in each group) (b). Diabetes
significantly decreased the flap survival ratio after flap surgery for 7 days (c). The histological staining of skin architecture in healthy and diabetic
flaps (d). Data are expressed as mean ± standard deviation
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molecular signals and decreasing the numbers of animals
and therapeutic cells used in future studies.
Discussion
After the initial description of the rat ischemic flap
model by McFarlane et al. in 1965, there were numerous
studies using the “McFarlane flap” to study the “delay
phenomenon” or critical flap survival [10, 20–22]. Sev-
eral modifications were adopted to decrease the uncer-
tainty of flap survival, such as varying flap dimensions
from 2 × 9 cm to 3 × 10 cm, raising the flap from either
the cranial or caudal end, or changing the flap according
to different anatomical (bony) landmarks. All of these at-
tempts were to minimize the large variation in flap sur-
vival (from 50 % to 75 % in the traditional McFarlane
flap). The most significant feature of these modifications
focused on the relationship of the flap to the underlying
anatomical structure by inclusion or exclusion of direct
cutaneous or musculocutaneous vessels in the flap [12].
In the McFarlane or modified McFarlane flap, one sili-
con membrane was placed underneath the skin flap to
prevent neovascularization from the underlying wound
bed. However, the neovascularization from the skin su-
ture edge might also be established from collateral vessel
formation, resulting in disturbance of the necrotic pat-
tern and an unpredictable flap survival [3].
When the flap chamber was used, the elevated three-
sided flap was fixed and separated from the underlying
wound bed and the adjacent skin (Fig. 1). This manner
ensured that the skin flap was supplied by one side of
the flap pedicle cranially. The survival pattern at the
distal portion of the flap was more stable in a linear
fashion, from cranial to caudal (Fig. 3a,b). A clear de-
marcation line could be observed not only macroscopic-
ally but also microscopically in histology, which could
not be observed in the “traditional” suture method. In
addition, the architecture of skin and skin appendage
was apparently different across the demarcation line his-
tologically (Fig. 3d,e). In addition, the clear demarcation
line of skin necrosis in the flap chamber model revealed
a distinct decrease of vascular density immediately
across the demarcation line by IHC stain of vWF and α-
SMA (Fig. 4). The suture model did not show such dra-
matic change of vasculature across the demarcation line.
This chamber could be used to stabilize the outcome
in disease models, such as a diabetic flap model. It is
well known that diabetes impairs ischemia-driven neo-
vascularization and causes fewer collateral circulation
vessels in both animal and human tissues [23, 24]. Any
confounder of such fragile microcirculation in the dia-
betic ischemic flap might lead to widely variable results.
When the flap chamber in a diabetic ischemic skin flap
was used, consistent flap survival of 50 % could be
achieved, a significant difference from the control model
(Fig. 5b,c). Our chamber provided similar histology re-
sults in the diabetic skin flap and revealed homogenous
atrophy in both the hypodermal and dermal layers
(Fig. 5d), including significant reductions in capillary
density and dermal thickness that agreed with skin ne-
crosis reported in previous studies [25, 26]. In addition,
the demarcation line was seen very clearly, with no diffi-
culty in evaluating the survival grossly, as compared with
the vague, uneven distribution in the traditional McFarlane
flap in diabetic rats [25, 26].
To apply the ischemic flap model to various types of
projects, a versatile modification could easily be made
while maintaining stability. As for the field of stem cell
therapy research, the ideal therapeutic window could be
created simply by changing the scale of the chamber de-
sign. As shown in Fig. 6, changing the chamber from
the original dimensions (3.6 × 7.2 cm) to a narrower
(3 × 10 cm) feature could significantly decrease the flap
survival from 80 % to 20 %. By implantation of HUVECs
3 days before surgery, the ischemic flap could be sal-
vaged significantly from 20 % to 40 %. This result dem-
onstrated that by using the flap chamber, the flap
survival was predictable with or without stem cell ther-
apies. The dimension of the flap chamber was versatile
and could be modified to create different therapeutic
windows for corresponding stem cells to treat.
a
b
Fig. 6 Modification of flap chamber for cell therapy. Gross pictures
for flap survival between original (3.6 × 7.2 cm, 20 g), narrow (3 × 10 cm,
17 g), and cell therapy in narrow chamber by human umbilical vein
endothelial cells (HUVECs) (Narrow + HUVEC) (a). The increase of
flap necrosis in the narrow chamber was salvaged by application of
HUVECs (n = 4 in each group) (b). Data are expressed as
mean ± standard deviation
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Conclusions
This novel ischemic flap chamber could stabilize the
results of variable skin necrosis in animal studies of
the traditional McFarlane flap. By changing the scale
in width-to-length ratio of this chamber, it is made to
fit well to both the healthy and disease models of
ischemic flaps. In addition, it is feasible to apply to the
model to stem cell therapy with stable therapeutic
outcomes.
Additional file
Additional file 1: Figure S1. Detailed scale for three-layer flap chamber
in different width-to-length ratio. (PPTX 535 kb)
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